Elan "add"
newratings.com - USA
... The analyst expects the once-daily, oral dose of FTY720 to gain market acceptance going forward, despite the clinical superiority of Tysabri. ...

New MS pill on the horizon
abc13.com - Houston,TX,USA
... This is important because other MS drugs, primarily Tysabri, have been linked to serious side effects, such as progressive multifocal leukoencephalopathy, the ...

UPDATE 1-Biogen signs licensing deal for hypertension drug
Reuters - USA
... Cambridge, Massachusetts-based Biogen, whose multiple sclerosis drug Tysabri was recently reintroduced after a safety scare, will pay mondoBIOTECH $7.5 million ...
See all stories on this topic

Genzyme Shares Too Cheap To Ignore: Report
Forbes - USA
... Bear Stearns biotech analyst Mark Schoenebaum pointed out that Tysabri, the multiple sclerosis drug withdrawn from the market by Biogen Idec (nasdaq: BIIB ...
See all stories on this topic

FTY720

Swiss shares higher in morning trade tracking Wall Street ...
Forbes - USA
... Also amongst the top gainers was Novartis, up 0.45 sfr at 71.85 on news that tests for both diabetes drug Galvus and MS drug FTY720 were successful, dealers ...

Euroshares open higher after Dow reaches 4 month highs - UPDATE
Forbes - USA
... of 53.2 eur. Novartis added 0.63 pct on news of successful tests for both diabetes drug Galvus and MS drug FTY720. Sanofi-Aventis ...

Businessman to submit development proposal
Boston Globe - United States
... said more than 1,000 patients will be participating, divided into equal numbers and randomly assigned to receive the Novartis pill, dubbed FTY720, at a dose of ...

Serono Sentiment Down As Rival Pdt Progresses
newratings.com - USA
The Novartis drug, dubbed FTY720, is a potential competitor to Serono's injectable MS drug Rebif. Rates reduce with fair value pegged at CHF740. ...

Novartis says MS pill shows significant benefits
Reuters - USA
... Clinical trial results show significant benefits for patients with relapsing multiple sclerosis treated with Novartis's experimental FTY720 medicine, the ...
See all stories on this topic

Novartis says tests successful for diabetes drug Galvus, MS drug ...
Hemscott - London,UK
... Novartis also said that phase II studies of multiple sclerosis drug FTY720 showed significant benefits for patients suffering from relapsing multiple sclerosis ...

---

fingolimod

Phase 2 Data Showing Clinical Benefits of Novel Once-Daily Oral ...
DG News - USA
EAST HANOVER, NJ -- September 14, 2006 -- Clinical trial results published in the New England Journal of Medicine showed that FTY720 (fingolimod), a novel once ...
See all stories on this topic

New MS Pill on the Horizon
ABC News - USA
... An international group of researchers gave different doses of the experimental drug Fingolimod to 255 patients suffering from relapsing MS, a specific form of ...
See all stories on this topic

An Experimental New Drug Might Be Effective In Treating MS
MedIndia - India
Studies indicate that ‘Fingolimod’, a new oral drug that is being developed for multiple sclerosis might prove effective. The ...
See all stories on this topic

---